Europska Unija - hrvatski - EMA (European Medicines Agency)

biogen netherlands b.v. - dimetil fumarat - multipla skleroza - imunosupresivi - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Europska Unija - hrvatski - EMA (European Medicines Agency)

eli lilly netherlands - pemetrekseda - carcinoma, non-small-cell lung; mesothelioma - antineoplastična sredstva - kancerogen плевральный mesotheliomapemetrexed lilly u kombinaciji s цисплатином indiciran za liječenje naivne kemoterapije u bolesnika s operirati raka mesothelioma плевры. Немелкоклеточного pluća cancerpemetrexed lilly u kombinaciji s цисплатином indiciran za prvu liniju terapije bolesnika s lokalno-uobičajena ili metastatskih немелкоклеточным raka pluća nego drugi uglavnom плоскоклеточной гистологией. Пеметрексед lilly prikazan kao monoterapija za liječenje местнораспространенного ili метастатического немелкоклеточного raka pluća, druge, nego pretežno плоскоклеточного гистологии kod pacijenata, bolest kojoj se ne прогрессировало odmah nakon kemoterapije платиносодержащей. Пеметрексед lilly prikazan kao monoterapija za drugu liniju terapije kod bolesnika sa lokalno-održao ili метастатического немелкоклеточного raka pluća druge, nego u osnovi плоскоклеточной гистологией.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pharmathen s.a. - irbesartana - hipertenzija - sredstva koja djeluju na sustav renin-angiotenzina - sabervel je indiciran kod odraslih osoba za liječenje esencijalne hipertenzije. također indiciran za liječenje zatajenja bubrega kod odraslih pacijenata sa dijabetes hipertenzija i tip 2 u sastavu antihipertenzivnih lijekova hrane .

Europska Unija - hrvatski - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - macimorelin acetat - metode dijagnostike, endokrini - macimorelin - ovaj je lijek samo za dijagnostičku uporabu.  ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.

Europska Unija - hrvatski - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinom, squamous cell - antineoplastična sredstva - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

elektroničar d.o.o. karlovačka cesta 26/a 10000 zagreb -

Europska Unija - hrvatski - EMA (European Medicines Agency)

qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - psi - za liječenje neupotrebljiva, bez udaljenih metastaza (koji na pozornici) potkožnog pretilih stanica tumora, koji se nalazi na razini ili distalno na lakat ili skočnog zgloba kuka, i neupotrebljiva, sobe метастатические uzeli stanice kože рангоута tumora kod pasa.

Europska Unija - hrvatski - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - tumori gastrointestinalnog stroma - drugi antitumorski lijekovi, inhibitori протеинкиназы - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Europska Unija - hrvatski - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Europska Unija - hrvatski - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - ostali lijekovi protiv živčanog sustava - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.